BACKGROUND: Superior treatment response and survival for patients with human papilloma virus (HPV)-positive head and neck cancer (HNSCC) are documented in clinical studies. However, the relevance of high-grade acute organ toxicity (HGAOT), which has also been correlated with improved prognosis, has attracted scant attention in HPV-positive HNSCC patients. Hence we tested the hypothesis that both parameters, HPV and HGAOT, are positive prognostic factors in patients with HNSCC treated with definite radiotherapy (RT) or radiochemotherapy (RCT). PATIENTS AND METHODS: Pretreatment tumor tissue and clinical records were available from 233 patients receiving definite RT (62 patients) or RCT (171 patients). HPV infection was analysed by means of HPV DNA detection or p16(INK4A) expression; HGAOT was defined as the occurrence of acute organ toxicity >grade 2 according to the Common Toxicity Criteria. Both variables were correlated with overall survival (OS) using Cox proportional hazards regression. RESULTS: Positivity for HPV DNA (44 samples, 18.9 %) and p16(INK4A) expression (102 samples, 43.8 %) were significantly correlated (p < 0.01), and HGAOT occurred in 77 (33 %) patients. Overall, the 5-year OS was 23 %; stratified for p16(INK4A) expression and HGAOT, OS rates were 47 %, 42 %, 20 % and 10 % for patients with p16(INK4A) expression and HGAOT, patients with HGAOT only, patients with p16(INK4A) expression only, and patients without p16(INK4A) expression or HGAOT, respectively. After multivariate testing p16(INK4A) expression (p = 0.003) and HGAOT (p < 0.001) were significantly associated with OS. CONCLUSION: P16(INK4A) expression and HGAOT are independent prognostic factors for OS of patients with HNSCC, whereas p16(INK4A) expression is particularly important for patients without HGAOT.
BACKGROUND: Superior treatment response and survival for patients with human papilloma virus (HPV)-positive head and neck cancer (HNSCC) are documented in clinical studies. However, the relevance of high-grade acute organ toxicity (HGAOT), which has also been correlated with improved prognosis, has attracted scant attention in HPV-positive HNSCC patients. Hence we tested the hypothesis that both parameters, HPV and HGAOT, are positive prognostic factors in patients with HNSCC treated with definite radiotherapy (RT) or radiochemotherapy (RCT). PATIENTS AND METHODS: Pretreatment tumor tissue and clinical records were available from 233 patients receiving definite RT (62 patients) or RCT (171 patients). HPV infection was analysed by means of HPV DNA detection or p16(INK4A) expression; HGAOT was defined as the occurrence of acute organ toxicity >grade 2 according to the Common Toxicity Criteria. Both variables were correlated with overall survival (OS) using Cox proportional hazards regression. RESULTS: Positivity for HPV DNA (44 samples, 18.9 %) and p16(INK4A) expression (102 samples, 43.8 %) were significantly correlated (p < 0.01), and HGAOT occurred in 77 (33 %) patients. Overall, the 5-year OS was 23 %; stratified for p16(INK4A) expression and HGAOT, OS rates were 47 %, 42 %, 20 % and 10 % for patients with p16(INK4A) expression and HGAOT, patients with HGAOT only, patients with p16(INK4A) expression only, and patients without p16(INK4A) expression or HGAOT, respectively. After multivariate testing p16(INK4A) expression (p = 0.003) and HGAOT (p < 0.001) were significantly associated with OS. CONCLUSION:P16(INK4A) expression and HGAOT are independent prognostic factors for OS of patients with HNSCC, whereas p16(INK4A) expression is particularly important for patients without HGAOT.
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: Grace C Blitzer; Molly A Smith; Stephen L Harris; Randall J Kimple Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-15 Impact factor: 7.038
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: Hendrik A Wolff; Benjamin Daldrup; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M W Roedel; Hans Christiansen Journal: Radiology Date: 2011-03 Impact factor: 11.105
Authors: F Bussu; M Sali; R Gallus; V G Vellone; G F Zannoni; R Autorino; N Dinapoli; R Santangelo; R Martucci; C Graziani; F Miccichè; G Almadori; J Galli; G Delogu; M Sanguinetti; G Rindi; V Valentini; G Paludetti Journal: Br J Cancer Date: 2013-02-12 Impact factor: 7.640
Authors: S Nagl; M Haas; G Lahmer; M Büttner-Herold; G G Grabenbauer; R Fietkau; L V Distel Journal: Oncoimmunology Date: 2016-01-13 Impact factor: 8.110
Authors: Margret Rave-Fränk; Narges Tehrany; Julia Kitz; Martin Leu; Hanne Elisabeth Weber; Peter Burfeind; Henning Schliephake; Martin Canis; Tim Beissbarth; Holger Michael Reichardt; Hendrik Andreas Wolff Journal: Strahlenther Onkol Date: 2015-09-15 Impact factor: 3.621
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Pia B Erben; Kathrin Brunner; Markus Hecht; Marlen Haderlein; Maike Büttner-Herold; Abbas Agaimy; Rainer Fietkau; Arndt Hartmann; Luitpold V Distel Journal: Int J Clin Exp Pathol Date: 2015-12-01
Authors: Beat Bojaxhiu; Arnoud J Templeton; Olgun Elicin; Mohamed Shelan; Kathrin Zaugg; Marc Walser; Roland Giger; Daniel M Aebersold; Alan Dal Pra Journal: Radiat Oncol Date: 2018-11-06 Impact factor: 3.481
Authors: Annett Linge; Stefan Schmidt; Fabian Lohaus; Constanze Krenn; Anna Bandurska-Luque; Ivan Platzek; Cläre von Neubeck; Steffen Appold; Alexander Nowak; Volker Gudziol; Frank Buchholz; Gustavo B Baretton; Michael Baumann; Steffen Löck; Mechthild Krause Journal: Clin Transl Radiat Oncol Date: 2019-03-18
Authors: Beat Bojaxhiu; Binaya K Shrestha; Pascal Luterbacher; Olgun Elicin; Mohamed Shelan; Andrew J S Macpherson; Benjamin Heimgartner; Roland Giger; Daniel M Aebersold; Kathrin Zaugg Journal: Radiat Oncol Date: 2020-12-14 Impact factor: 3.481
Authors: Manuela Schwegler; Anna M Wirsing; Hannah M Schenker; Laura Ott; Johannes M Ries; Maike Büttner-Herold; Rainer Fietkau; Florian Putz; Luitpold V Distel Journal: Biomed Res Int Date: 2015-10-04 Impact factor: 3.411